Cleveland, Ohio
Cancer clinical trials in Cleveland, OH
205 cancer studies are recruiting participants at sites in Cleveland as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Cleveland at a glance
- 205 studies are recruiting at a site in Cleveland.
- By phase: Phase 1 (37), Phase 1/2 (41), Phase 2 (36), Phase 2/3 (9), Phase 3 (53), Phase 4 (1), No phase (20), Observational (8). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (131), university, hospital or other (54), government (20).
- By research area: Lung Cancer (63), Lymphoma (47), Breast Cancer (43), Prostate Cancer (31), Pancreatic Cancer (11), Melanoma (10).
- Most recent update to one of these records: November 16, 2026.
Breast cancer studies recruiting in Cleveland
Basic details from each study's public record (the 30 most recently updated of 205). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- LeonaBio
- Study site
- University Hospitals Seidman Cancer Center
- Registry record
- NCT05696626 · updated
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study sites
- Case Western Reserve University · Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation
- Registry record
- NCT03418961 · updated
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Case Western Reserve University
- Registry record
- NCT05564377 · updated
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- MetroHealth Medical Center
- Registry record
- NCT06058377 · updated
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- Phase 1
- Ages 18 to 55
- Female participants
- Sponsor
- TerSera Therapeutics LLC
- Study site
- Cleveland Clinic Foundation
- Registry record
- NCT07310420 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.
Lung cancer studies recruiting in Cleveland
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Case Western Reserve University
- Registry record
- NCT06287775 · updated
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Novelty Nobility, Inc.
- Study site
- Case Comprehensive Cancer Center
- Registry record
- NCT06805825 · updated
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center
- Registry record
- NCT07111520 · updated
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation · MetroHealth Medical Center
- Registry record
- NCT04267848 · updated
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Case Western Reserve University
- Registry record
- NCT04665739 · updated
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Boehringer Ingelheim
- Study site
- Cleveland Clinic
- Registry record
- NCT04886804 · updated
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Phase 3
- Ages 70 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Case Western Reserve University · MetroHealth Medical Center
- Registry record
- NCT06096844 · updated
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- University Hospitals Cleveland Medical Center
- Registry record
- NCT06758401 · updated
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- University Hospitals Cleveland Medical Center
- Registry record
- NCT07100080 · updated
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Cleveland Clinic - Ohio ( Site 0016)
- Registry record
- NCT07221474 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.
Prostate cancer studies recruiting in Cleveland
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University Hospitals Cleveland Medical Center ( Site 0043)
- Registry record
- NCT06136624 · updated
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
- No phase
- Ages 18 and older
- Male participants
- Sponsor
- Axonics, Inc.
- Study site
- University Hospitals Cleveland
- Registry record
- NCT06511141 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.
Melanoma studies recruiting in Cleveland
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- Phase 3
- Ages 75 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Case Western Reserve University
- Registry record
- NCT07068074 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cleveland, OH on ClinicalTrials.gov.
Lymphoma studies recruiting in Cleveland
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Nurix Therapeutics, Inc.
- Study site
- The Cleveland Clinic Foundation
- Registry record
- NCT07221500 · updated
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study sites
- Cleveland Clinic Main ( Site 0101) · Fairview Hospital-Moll Cancer Center ( Site 0198) · University Hospitals of Cleveland ( Site 0155)
- Registry record
- NCT06890884 · updated
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University Hospitals of Cleveland ( Site 0113)
- Registry record
- NCT07519772 · updated
A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- University Hospitals of Cleveland ( Site 1321)
- Registry record
- NCT07634471 · updated
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation
- Registry record
- NCT04269902 · updated
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- Ages 1 to 30
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Rainbow Babies and Childrens Hospital
- Registry record
- NCT04546399 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study sites
- Cleveland Clinic Foundation · Rainbow Babies and Childrens Hospital
- Registry record
- NCT05675410 · updated
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Regeneron Pharmaceuticals
- Study site
- University Hospitals Cleveland Medical Center
- Registry record
- NCT06091254 · updated
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Case Western Reserve University
- Registry record
- NCT06337318 · updated
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BeOne Medicines
- Study site
- University Hospitals
- Registry record
- NCT06846671 · updated
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Case Western Reserve University
- Registry record
- NCT07003295 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cleveland, OH on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Cleveland
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Incyte Corporation
- Study sites
- Investigative Site US020 · Investigative Site US050
- Registry record
- NCT07522073 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.
Ask about studies near Cleveland
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Ohio
All Ohio locations
542 studies recruiting across 70 cities.
Columbus
269 studies recruiting.
Cincinnati
154 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections